Stiles Financial Services Inc Buys 262 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Stiles Financial Services Inc grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,358 shares of the biopharmaceutical company’s stock after buying an additional 262 shares during the quarter. Stiles Financial Services Inc’s holdings in Regeneron Pharmaceuticals were worth $2,291,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $27,000. Finally, Colonial Trust Advisors acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $32,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on REGN. Morgan Stanley reiterated an “overweight” rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $569.90 on Friday. The firm’s 50-day moving average price is $573.83 and its 200-day moving average price is $565.52. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,024.36. The firm has a market capitalization of $60.40 billion, a P/E ratio of 14.36, a P/E/G ratio of 1.81 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business earned $11.56 earnings per share. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.